Capital Advisory Group Advisory Services’s AMAG Pharmaceuticals AMAG Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-645	Closed	-$7K	–	462
2019 Q3	$7K	Hold	645	–	–	﹤0.01%	327
2019 Q2	$6K	Buy	+645	New	+$6.96K	﹤0.01%	333

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Advisory Group Advisory Services's AMAG Position: Q4 2019 in Review

Capital Advisory Group Advisory Services sold out of AMAG Pharmaceuticals (AMAG) in Q4 2019, closing a stake of 645 shares — an estimated $7K sold.

Capital Advisory Group Advisory Services first reported a position in AMAG in Q2 2019 and held it in 2 quarters. The position peaked at $7K in Q3 2019. 134 funds tracked by Wall St. Rank hold AMAG as of Q4 2019.

Capital Advisory Group Advisory Services reported no remaining AMAG Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 645 AMAG Pharmaceuticals shares in Q4 2019, an estimated $7K.
Capital Advisory Group Advisory Services first reported a position in AMAG Pharmaceuticals in Q2 2019 and held it in 2 quarters.
Capital Advisory Group Advisory Services's AMAG Pharmaceuticals position peaked at $7K in Q3 2019.
134 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2019.

Based on Capital Advisory Group Advisory Services's 13F filing for Q4 2019, filed 14 Feb 2020.